ANDA 90721, held by Novast Labs Ltd. Ethinyl Estradiol; Levonorgestrel.
As of Nov 16, 2026, ANDA 90721 (Falmina), held by Novast Labs Ltd, was first approved by FDA on Mar 28, 2012, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lutera is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of use: The efficacy of Lutera in women with a body mass index (BMI) of > 35 kg/m 2 has not been adequately evaluated. In a clinical trial with levonorgestrel and ethinyl estradiol tablets, 1,477 subjects had 7,720 cycles of use and a total of 5 pregnancies were reported. This represents an overall pregnancy rate of 0.84 per 100 woman-years. This rate includes patients who did not take the drug correctly. One or more pills were missed during 1,479 (18.8%) of the 7,870 cycles; thus all tablets were taken during 6,391 (81.2%) of the 7,870 cycles.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Falmina0.02MG;0.1MG · tablet;oral-28 | Ethinyl Estradiol; Levonorgestrel | Rx |
| Apr 29, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 28, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters